Vaegler M, DaSilva L A, Benz K, Amend B, Mollenhauer J, Aicher W K, Stenzl A, Sievert K-D
Klinische Forschergruppe 273, Universitätsklinik für Urologie, Tübingen, Deutschland.
Urologe A. 2014 Mar;53(3):354-61. doi: 10.1007/s00120-013-3353-8.
In Germany, 6-8 million woman and men suffer urinary incontinence, which represents 12.5 % of the population. It is estimated that by the middle of this century, it will increase to almost 30 %. The primary reason will be primarily related to the aging population but also to patient awareness and seeking a solution. In addition to the cost which is covered by the health insurance, the patient will spend more than half a billion euro/year out-of-pocket, not to mention the social stigma associated with urinary incontinence. The current common treatment options are symptomatic but do not restore functionality. One option might be tissue engineering or stem cell therapy. This article describes the likelihood that this therapy will change the approach in treating stress urinary incontinence. Boundaries and legal aspects are highlighted as well as approximated cost. These treatment costs might be currently higher than the standard treatment options, but the investment to reduce these costs are paid indirectly by society.
在德国，有600万至800万女性和男性患有尿失禁，占总人口的12.5%。据估计，到本世纪中叶，这一比例将增至近30%。主要原因首先与人口老龄化有关，但也与患者意识及寻求解决方案有关。除了医疗保险所涵盖的费用外，患者每年还将自掏腰包花费超过5亿欧元，更不用说与尿失禁相关的社会耻辱感了。目前常见的治疗方法只是缓解症状，无法恢复功能。一种选择可能是组织工程或干细胞疗法。本文描述了这种疗法改变压力性尿失禁治疗方法的可能性。文中强调了其界限和法律方面以及大致成本。目前这些治疗成本可能高于标准治疗方法，但降低这些成本的投资是由社会间接支付的。
